[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100559027":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":24,"centralContacts":28,"locations":36,"responsibleParty":52,"collaborators":10,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":10,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":10,"enrollmentInfo":63,"targetDuration":66,"studyType":67,"phases":10,"briefSummary":68,"conditions":69,"keywords":72,"overallStatus":39,"whyStopped":10,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Memorial Sloan Kettering Cancer Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Esophageal and Gastroesophageal Junction Cancer",null,"Patients will undergo assessment with the EORTC QLQ-C30 and QLQ-OGS25 questionnaires. Those patients who undergo local therapy will occur at baseline, months 7-9 within 45 days of local therapy, and one year\u002Ftime of progression. Those patients who do not undergo local therapy will undergo assessment at baseline, at 6 months, and at one year.",[13,14],"Other: EORTC QLQ-C30 questionnaire","Other: QLQ-OGS25 questionnaire",[16,20],{"type":6,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"EORTC QLQ-C30 questionnaire","The EORTC QLQ-C30 has 30 items arranged into 9 scales and 6 single items. The scales are divided into 5 function scales (physical, role, cognitive, emotional, and social function), 3 symptom scales (fatigue, pain, and nausea or vomiting), and 1 global health status\u002Fquality-of-life scale. The 6 single items address specific symptoms (dyspnea, appetite loss, insomnia, constipation, and diarrhea) and the financial impact of the disease. Each item has 4 response alternatives: (1) \"not at all,\" (2) \"a little,\" (3) \"quite a bit,\" and (4) \"very much,\" except for the global health status\u002Fquality-of-life scale, which has response options ranging from (1) \"very poor\" to (7) \"excellent.\" For analysis, all questionnaire responses will be transformed into scores on a linear scale of 0 to 100 in accordance with the EORTC scoring manual. Mean scores with standard deviations will be calculated, with a higher score indicating a better health-related quality of life.",[9],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"QLQ-OGS25 questionnaire","The QLQ-OGS25 is specific for esophageal, GEJ, or gastric cancer and consists of a symptom scale only. The QLQ-OGS25 has 6 scales: dysphagia, eating restrictions, reflux, odynophagia, pain, and anxiety. Scales have good reliability (α range, 0.67-0.87), and they distinguish between tumor sites and disease stage. The response format is a 4-point Likert scale. Responses to the questionnaires will be transformed into a scale of 0 to 100 using the EORTC guidelines, with a higher score indicating a deterioration of symptoms.",[9],[25],{"name":26,"affiliation":5,"role":27},"Daniela Molena, MD","PRINCIPAL_INVESTIGATOR",[29,33],{"name":26,"role":30,"phone":31,"phoneExt":10,"email":32},"CONTACT","212-639-3870","molenad@mskcc.org",{"name":34,"role":30,"phone":35,"phoneExt":10,"email":10},"Geoffrey Ku, MD","646-888-4588",[37],{"facility":38,"status":39,"city":40,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Memorial Sloan Kettering Cancer Center (All Protocol Activities)","RECRUITING","New York","10065","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-74.00597,40.71427,{"lat":48,"lon":47},[51],{"name":26,"role":30,"phone":31,"phoneExt":10,"email":10},{"type":53,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100559027","registry-for-esophageal-and-gastroesophageal-junction-cancer-100559027",false,"NCT06558786","Registry for Esophageal and Gastroesophageal Junction Cancer","Prospective Registry Study of Multimodality Therapy for Oligometastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction","Inclusion Criteria:\n\n* Newly diagnosed stage IV adenocarcinoma of the esophagus or GEJ with OMD at the time of diagnosis, defined as the following:\n* Retroperitoneal lymph nodes (e.g., para-aortal, intra-aorto-caval, parapancreatic, or mesenterial lymph node)\n* Liver\n* Lung\n* Extra-abdominal lymph nodes (e.g., supraclavicular or cervical lymph nodes)\n* Adrenal gland\n* Unilateral or bilateral ovarian metastases (in the absence of gross or microscopic peritoneal disease \\[positive cytology\\])\n* Bone\n* ≤2 sites of disease (excluding the primary tumor and regional lymph nodes)\n* ≤3 tumors within each organ system\n* ≤5 metastases\n* All nonregional lymph nodes (including cervical, supraclavicular, and retroperitoneal nodal disease) are considered 1 discrete lesion\n* Satellite lesions in the primary esophageal malignancy, such as skipped esophageal primaries, are not considered metastatic sites\n* All sites of disease must be amenable to complete local therapy after systemic therapy, according to the treating physician. Treatment modalities include:\n* Surgery\n* Definitive chemoradiation\n* Stereotactic radiation\n* Ablation or similar techniques (e.g., irreversible electroporation)\n* Age ≥18 years\n\nExclusion Criteria:\n\n* Presence of metastases, at the time of diagnosis, to the following:\n\n  * Peritoneum, including positive peritoneal lavage (on the basis of baseline diagnostic laparoscopy to rule out gross disease and positive peritoneal lavage cytology; laparoscopy may be omitted for patients in whom all sites of disease are above the diaphragm)\n  * Malignant pleural effusion\n  * Brain metastases or leptomeningeal disease\n  * Other sites not specifically noted must be reviewed and approved by the PIs\n  * Any site of disease that is not amenable to definitive local therapy\n* Unfit for best systemic therapy\n* Metachronous OMD\n* Secondary primary cancer, with the exclusion of basal cell carcinoma of the skin\n* Pregnant, lactating, or intending to become pregnant\n* Unwilling to provide informed consent","ALL","18 Years",{"count":64,"type":65},50,"ESTIMATED","2 Years","OBSERVATIONAL","The purpose of this registry study is to create a database-a collection of information-for better understanding standard treatments for esophageal and Gastroesophageal Junction Cancer\u002FGEJ cancer. Researchers will use the information from this database to learn more about the effectiveness of different treatment options.",[70,71],"Gastroesophageal-junction Cancer","Esophageal Cancer",[73,74],"Quality-of-Life Assessments","24-206","2026-05-19",{"date":77,"type":78},"2026-05-22","ACTUAL",{"date":80,"type":78},"2024-08-12",{"date":82,"type":65},"2029-08-12",{"name":5,"class":6},1]